- Built to Serve: The Day That Reminds Us Why We Chose Dentistry
- Journalists Catch You Up on Fauci Hearing, Peptides, and Kids’ Caffeine Consumption
- CMS finalizes 2.3% hospital pay bump, mandatory joint replacement model: 9 things to know
- How ambulatory shifts are reshaping perioperative strategy
- Cyclosporiasis cases top 18,000: 3 updates
- How Allegheny Health Network Strengthened its Foundation for IV Compounding Safety with Automation and Standardization¹
- Health plan customer service reps have AI in their ear
- Centene’s buyouts could have a $315M+ price tag for the rest of the year
- Medicare pay cut sparks specialty battle over skin cancer care
- Cardiovascular Institute of New England provides notice of data incident
- CMS locks in 2.3% inpatient hospital base pay increase, nudges back CJR-X Model start date
- Why autonomy — not just capital — is winning over cardiologists
- The $36 vs. $95 problem: How RVU negotiations are skewing physician pay
- Mississippi hospital board member, former CEO remembered as advocate for rural communities
- Pennsylvania SUD treatment locator reaches 146K users
- Top 10 dental, DSO stories in July
- Ohio youth treatment facility faces scrutiny over reported abuse: 8 notes
- What dental leaders told us in July
- Urban hospital closures and net change, by state
- Nebraska launches dashboard tracking rural health funds
- ADSO sues Colorado Dental Board over practice ownership rule
- New patient acquisition is the top growth driver for dental practices: Report
- 20 new behavioral health projects to know
- Nurses, patients protest North Star Health Alliance ASC closure
- No Surprises Act under attack by payers: 8 things to know
- Dental staffing wages up 23% since 2021: ADA
- AtlantiCare appoints anesthesiology, gastroenterology physician leaders
- Consumer dental spending up 24% over 10 years: 5 stats to know
- Baylor Scott & White joint venture expands outpatient behavioral health services
- 5 DSOs making headlines
- VA to explore GLP-1 treatment for alcohol use disorder: 4 notes
- A $5B wave of M&A hits the ASC industry
- FTC Sues Hims & Hers Over Health Privacy And Billing Practices
- 145 physician medical groups led all healthcare M&A sectors in Q1
- 10 new ASCs in July
- Healthcare exec, telemedicine company owner sentenced for $35M DME fraud scheme
- Amylyx demystifies post-bariatric hypoglycemia with patient education website
- What Dad Eats Before Conception May Influence Baby's Health
- Family History Plays Role In Genetic Risk For Breast Cancer, Researchers Find
- A look at employers' attitudes toward ICHRAs
- Revised 340B Rebate Model Pilot Program moves forward, despite provider pushback
- Function Health lands $450M in growth financing to scale tech-enabled preventive health
- Daiichi Sankyo flags accounting error, as shares tank despite revenue beat
- AbbVie's Skyrizi shrugs off new competition as it thrives in growing psoriasis market
- Op-ed: Hospitals on the edge, a time for CMS to do no harm
- Daily Routine Key To Good Health, Study Says
- Alignment Healthcare boasts 32% revenue jump in Q2, lifts 2026 outlook
- Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis
- Psilocybin Therapy Helps Ease Veterans' Severe PTSD, Pilot Study Finds
- Newsom Reverses On Long-Sought Paid Leave Benefit For California Teachers
- Nicotine Levels Are Rising Among Teens Who Vape, New Study Warns
- The Newest Federally Recognized Tribe Wants Better Healthcare. It May Be On Its Own.
- They Worked To Protect Public Health. Now They Want the Public’s Votes.
- 27 new behavioral health study findings to know
- 21 state behavioral health policy updates
- What will fuel the next wave of DSO growth
- Dentists’ biggest staffing headaches
- Shionogi makes the call on COVID pill Xocova TV spot
- Psilocybin-assisted therapy reduced PTSD symptoms: 3 notes
- Fierce Pharma Asia—Legend CEO exits; Merck’s hush-hush PD-1xVEGF plan; Otsuka’s novel ADHD nod
- Psychedelics, peptides and GLP-1s
- How 'physician-led' care team models tackle primary care's workforce problem
- How 7 systems divert behavioral health patients from the ED
- WellSpan Health, Hippocratic AI ink ‘multi-year’ partnership with plans to co-develop clinical AI agents
- Kaiser faces complaint over automated behavioral health triage system
- Free research hub Nila aims to demystify menopause, other hormone conditions
- Scientists Defend Fauci's Pandemic Work As Senate Hearing Turns Bitter
- Pfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbVie
- Study Questions Effectiveness of Antihistamines in Easing Eczema
- Vaping Is Likely Reshaping The Future Of Cancer In The US, Study Argues
- Weekly Rundown: Counsel Health rolls out white label AI care platform; Community Health Network launches MyChart AI assistant
- New CEO Garijo sketches out vision to reverse Sanofi's fortunes as Q2 delivers impressive sales beat
- Alnylam shares tank 29% as Amvuttra disappoints with ATTR outlook cut for 2026
- Waystar boosts 2026 outlook as AI-powered RCM solutions gain traction with providers
- YouTuber MrBeast welcomes Amgen to the channel, kicking off pediatric cancer funding effort
- Booming Dupixent sales fuel Regeneron's biggest quarter since pandemic
- Sugar Consumption Early In Life Linked To Increased Dementia Risk, World War II-Era Data Show
- Work Stress Harming Middle-Age Sleep, Study Says
- RFK Jr.'s Gardasil litigation ties subject to fresh lawmaker scrutiny after Merck settlement
- Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
- Hospice's Bad Reputation Amid Fraud Crisis Will Hurt Patients, Industry Experts Warn
- Cell Phone Ownership Linked To Lower Reading Skills In Elementary Students
- Listen to the Latest ‘KFF Health News Minute’
- Medicaid Insurers’ Contracts on the Line in Tight Governor’s Race
- Abortion Drug Law in Louisiana Heightens Hemorrhage Risk for Pregnant Patients
- Teladoc Health trims 2026 revenue forecast amid challenges with BetterHelp insurance shift
- Cigna CEO: Express Scripts seeing 'significant early interest' from clients for new rebate-free PBM model
- Viatris runs into FDA roadblock after advertising on-the-go use of cystic fibrosis inhaler
- Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
- FTC sues Hims & Hers over data privacy, billing practices
- CMS' proposed 340B reimbursement cut—who wins, and who loses?
- Virtual care helps patients improve their gambling disorder symptoms, Birches Health finds
- Case Western Reserve University launches next-generation healthcare leadership program
- Lilly, Resilience commit $750M to boost US diabetes, obesity med production
- CMS ending Medicare Part D subsidy program
- Red Cross Declares Rare National Blood Supply Crisis Amid Summer Shortfall
- Not Just Pregnancy Fatigue: Could It Be Sleep Apnea?
- More Women Drinking During Pregnancy
- Wellstar Health System lays off 761 corporate, administrative staff
- Biogen flips '26 guidance from expected decline to sales increase
- Teva’s innovation engine offsets generics slump, leaving one analyst ‘shocked’ by Ajovy’s surge
- Talking To Your Baby? Eye Contact Is Key To Language Development, Experiment Shows
- Boosted by CMS settlement, Incyte expects Opzelura to cross $1B in 2026
- Leapfrog launches expanded ASC public reporting program
- Cyclospora Boosts Fears That Deadlier Foodborne Outbreaks Are Ahead
- DoorDash, GrubHub Delivering Junk Food To 1 In 4 Teens During School Hours
- Uninsured but Undaunted, a Surgical Patient Searched the Globe for a Deal
- Trump Has Quietly Throttled an Agency Devoted to the Safety of American Healthcare
- Hospice’s Bad Reputation Amid Fraud Crisis Will Hurt Patients, Industry Experts Warn
- Humana plans more market exits for 2027, CFO says
- PMCPA sanctions melatonin drugmaker over misleading information
- CG Life embraces next-gen era in merger with AI-native agency The Considered+AI
- How 2 FDA citations complicate Hengrui, Elevar’s push for liver cancer combo approval
- Fifth Death Reported In NYC Legionnaires' Disease Outbreak
- Many Young Adults Aren't Ready To Manage Their Own Healthcare, Poll Finds
- Can A Daily Multivitamin Help You Stay Active As You Age?
- Stellarus launches AI-powered health plan customer service representative copilot
- Prebiotic Soda Health Claims Questioned In New Nutrition Study
- Family-Based Childhood Obesity Program Helps Kids Cut Weight, Become Healthier
- To Afford Aging In Place, Older Adults Turn To 'Golden Girls' Housing
- Breakfast Can Help Teens Make Better Food Choices Throughout Their Day, Study Says
- Newsom Reverses on Long-Sought Paid Leave Benefit for Teachers in California
- FDA Panel Backs Two Peptides For Compounding, Rejects One
- How Accurate Are Photo-Based Calorie Apps? 4 Are Put To The Test
- Popular School Cafeteria Meals Need An Update To Meet Healthy Food Standards, Researchers Say
- Ovarian Syndrome Quadruples Heart Disease Risk In Women, Major Study Concludes
- Weed-Killing Chemical, Glyphosate, Linked To Premature Births In Humans, Study Says
- 'The Child Is Terrified': Doctors On Front Lines Of Measles Comeback Speak Out
- 'Yo-yo' Weight Loss Linked To Decline In Muscle Mass
- FDA Advisers Dismiss Safety Warnings, Back Four Peptide Treatments
- Frequent Marijuana Use Linked To Higher Stress Hormone Levels
- Back Pain? Try Swimming, Study Says
- Ozempic Cuts Down Calorie Intake For At Least A Year, Even If Hunger Returns, Trial Finds
- Money Problems Might Make Your Brain Old Before Its Time, Study Suggests
- Black MS Patients Dying Younger Than White Ones, Study Finds
- Headstands and Summervaults: A Statement on Crypto Vaults and Lending Strategies
- Remarks at the Small Business Capital Formation Advisory Committee Meeting
- Seeking Public Comment on Seeking Public Capital: Remarks Before the Small Business Capital Formation Advisory Committee
- Remarks to the Small Business Capital Formation Advisory Committee
- Statement on Regulation E-Delivery
- Paper Taper: Statement on Proposed Regulation E-Delivery
- Statement on Proposed Regulation E-Delivery
- Senate HELP committee advances nominees for CDC director, HHS preparedness head
- Remarks before the American-Hellenic Chamber of Commerce
- Remarks at the Society for Corporate Governance Conference
- Zimmer Biomet to Hire 500 in India as New Bengaluru Technology Centre Drives AI and MedTech Innovation
- Zimmer Biomet to Hire 500 in India as New Bengaluru Technology Centre Drives AI and MedTech Innovation
- AdaptHealth Investigates Data Breach After Social Engineering Attack, Possible Link to ShinyHunters Emerges
- AdaptHealth Investigates Data Breach After Social Engineering Attack, Possible Link to ShinyHunters Emerges
- Statement on the 2026 Regulatory Agenda
Michigan healthcare freedom community forum
AG Nessel is serving her financial paymasters at the Michigan Association for Justice (MAJ), who have been campaigning for the State Legislature to gut the Michigan Supreme Court (MSC)'s Smith v. Globe Life Ins. Co. and Liss v. Lewiston-Richards, Inc. decisions.
AG Nessel Asks Michigan Supreme Court to Correct Past Decisions, Allow Insulin Investigation
August 04, 2023
LANSING – Michigan Attorney General Dana Nessel this week filed an application seeking leave to appeal an order preventing her from proceeding with an investigation of Eli Lilly and Company’s insulin pricing practices. Lilly has used two past decisions of the Michigan Supreme Court (MSC) to assert the Michigan Consumer Protection Act (MCPA) is inapplicable to its sale of insulin. The Attorney General is asking the Supreme Court to reverse those decisions because they are not supported by a plain reading of the law.
In January 2022, Nessel launched an investigation into Eli Lilly - one of the nation’s three largest drug-manufacturing companies producing insulin. The action sought to use the MCPA to investigate various aspects of Lilly’s pricing practices related to life-saving medications used by diabetics. Nessel also filed a companion Complaint for Declaratory Judgment, asking the court to declare that MCL 445.904(1)(a) does not prohibit an investigation into Eli Lilly’s insulin pricing. But Lilly used the two prior decisions to obtain an order stating that the consumer protection act does not apply to its insulin sales, thus halting the investigation.
“The Smith v. Globe Life Ins. Co. and Liss v. Lewiston-Richards, Inc. decisions have been used to frustrate consumer protection efforts for far too long,” Nessel said. “It is unconscionable for Michigan residents to have to choose between life-saving medicine and food or rent. My Consumer Protection Team stands ready to hold drug companies accountable for their unjustifiable prices, but we can only do so if we are not being hindered by court decisions that misapply the text of a law having a purpose obvious from its name.”
Last July, Ingham Circuit Judge Wanda M. Stokes granted Lilly’s motion for summary disposition, holding that the Smith v. Globe Life Ins. Co. and Liss v. Lewiston-Richards, Inc. decisions preclude application of the MCPA to Lilly’s sale of insulin medications because the general transaction of selling insulin is authorized by the Food and Drug Administration.
A claim of appeal was filed with the Court of Appeals (COA) along with a bypass application to the MSC. The MSC denied the bypass application but asked the COA to expedite the appeal. The COA upheld the lower court’s decision, leading to this week’s filing.
Smith (1999) and Liss (2007) interpret an exemption contained in Section 445.904(1)(a) of the MCPA as applying whenever the general transaction is specifically authorized by law, regardless of whether the specific misconduct alleged is prohibited. Under this interpretation, members of any industry that is generally regulated are often deemed exempt from the MCPA, thereby providing what is effectively a “free pass” for misconduct under the MCPA, regardless of how egregious the misconduct.
The Attorney General’s appeal is not based on the merits of whether Eli Lilly has violated the MCPA, but rather on the Attorney General’s authority to investigate possible MCPA violations under MCL 445.907 when Eli Lilly is generally authorized to sell insulin medications by the Food and Drug Administration (FDA) but is bound by no FDA regulations regarding the pricing of those medications.
The MCPA was enacted in 1976 and Attorney General Nessel is hopeful the legislature will take action to update the statute.
“Without the ability to wield the full authority provided by the act, my department is hobbled in its ability to investigate and hold accountable many regulated entities that may be ripping off Michigan consumers,” Nessel continued.
“In order for the Department of Attorney General to be the people’s watchdog when it comes to investigating the costs of prescription drugs, we must breathe life back into the Michigan Consumer Protection Act and revive the law’s original purpose to protect consumers. I look forward to working with the legislature to see that these critical changes are made to the statute.”
The Centers for Disease Control estimates that there are 34.2 million Americans with diabetes. In Michigan, the American Diabetes Association estimates that 865,000 people, or 11.2% of the adult population, have diabetes and that those with diabetes have medical expenses approximately 2.3 times higher than those who do not.
Those who wish to share their experience with the high cost of insulin are asked to fill out a consumer complaint form on the Attorney General's website. The Attorney General is interested in perspectives from consumers, pharmacists, and health professionals. If your concerns relate to the cost of a particular medication, please tell us the brand, product, and what (if anything) is covered by insurance.
Politics of greed. 😪
This is a battle of the lower depths. The real answer to high drug prices is more competition, not shifting profits from Big Pharma to parasitic lawyers.
This is true. It takes lawyers to produce this level of spin!
Michigan's Democrat-controlled Supreme Court heard Attorney General v Eli Lilly and Co (165961) yesterday. Attorney General Nessel is alleging that Eli Lilly's insulin pricing practices violate the Michigan Consumer Protection Act (MCPA). A three judge panel of the Michigan Court of Appeals threw out this case, but it appears that the Democrats on the Supreme Court want to reinstate it. We covered AG Nessel's initiation of this lawsuit two years ago in AG Nessel Seeks Reversal Of Michigan Supreme Court Rulings To Permit Investigation Of Eli Lilly Insulin Pricing:
The Case SummaryThe Attorney General seeks to investigate the cost of insulin medications manufactured by the defendant to determine whether the defendant’s pricing practices violate the Michigan Consumer Protection Act (MCPA). To that end, the Attorney General petitioned the Ingham Circuit Court for the issuance of civil investigative subpoenas under MCL 445.907. The Attorney General also filed a complaint seeking a declaratory judgment that the proposed investigation of the defendant’s pricing practices is not barred by the MCPA’s exemption for “transaction[s] or conduct specifically authorized under laws administered by a regulatory board or officer acting under statutory authority of this state or the United States.” MCL 445.904(1)(a). The complaint acknowledged that the Attorney General’s interpretation of the exemption is contrary to the construction given by the Supreme Court in Smith v Globe Life Ins Co, 460 Mich 446 (1999), and Liss v Lewiston-Richards, Inc, 478 Mich 203 (2007). The complaint alleged, however, that those cases were wrongly decided. The defendant moved for summary disposition under MCR 2.116(C)(8) (failure to state a claim), arguing that its transactions and conduct fall within the MCPA’s exemption based on the Smith and Liss decisions. The circuit court granted the motion and dismissed the Attorney General’s complaint. The Attorney General claimed an appeal of right in the Court of Appeals and then filed a bypass application in the Supreme Court. The Supreme Court denied the bypass application but directed the Court of Appeals to expedite its consideration of the case. The Court of Appeals affirmed the trial court in an unpublished opinion, holding that it was bound by Smith and Liss. The Supreme Court has ordered oral argument on the application to address: (1) whether the plaintiff adequately pled a claim that the defendant violated the Michigan Consumer Protection Act (MCPA), MCL 445.901 et seq.; (2) whether it is necessary for the plaintiff to adequately plead a violation of the MCPA for a court to determine whether MCL 445.904(1)(a), an exemption to the MCPA, applies; (3) whether this Court’s decisions in Smith v Globe Life Ins Co, 460 Mich 446 (1999), and Liss v Lewiston-Richards, Inc, 478 Mich 203 (2007), correctly interpreted MCL 445.904(1)(a); and (4) if they were incorrectly decided, whether they should nonetheless be retained under principles of stare decisis, Robinson v City of Detroit, 462 Mich 439, 463-468 (2000).
The Court of Appeals Dismissal:
The story from Michigan Advance:
Michigan Supreme Court hears argument in Nessel price gouging lawsuit against insulin drug maker
By Ben Solis - November 5, 2025Attorney General Dana Nessel’s ability to go after a major producer of insulin for price gouging was before the Michigan Supreme Court on Wednesday, with the state saying that it should be allowed to move forward in the matter despite previous court precedent noting otherwise.
Meanwhile, the attorney for the defendant in Attorney General v. Eli Lilly and Company said the attorney general’s office has failed to show an actual controversy exists and that this was an improper test case for the bounds of Michigan’s Consumer Protection Act.
The case centers around Nessel’s attempts to investigate the drug manufacturer to determine if its pricing practices for insulin violated the Michigan Consumer Protection Act. She asked the Ingham Circuit Court for subpoenas to gather information, and also filed a separate request for a judge to declare that her investigation wasn’t blocked by the act’s exemptions for activities already approved by government or regulatory agencies.
That motion noted that Nessel’s interpretation of the act was out of step with the Michigan Supreme Court’s decisions in Smith v. Globe Life Insurance Company and Liss v. Lewiston-Richards Inc. Nessel has asserted that both of those cases were wrongly decided.
The appellate court affirmed the circuit court’s decision to dismiss the case in an unpublished opinion, which means the opinion was not binding on the lower courts or necessarily instructive to the Michigan Supreme Court.
In court on Wednesday, Assistant Attorney General Darrin Fowler reupped those arguments, and asked the justices of the high court to reconsider its previous findings in those cases, as well as for a determination if the case can be ferreted out in state court using the consumer protection act.
A key part of that is showing the court that there has been an adversarial relationship between the two parties and that it was a dispute for the court to take up.
“Here, the Attorney General was not required to bring an investigative petition to launch an insulin investigation into Eli Lilly,” Fowler said. “What the attorney general was required to do under the declaratory judgment rule was to give evidence of a sincere intention to invoke the consumer protection act against Lilly in a way that would be adversarial and would implicate the section for exemption”
Fowler added that the office has spent nearly four years arguing about the Smith and Liss issues from the circuit court up to the Court of Appeals, and now before the state’s high court.
The bigger picture, Fowler said, was that the company is misconstruing the act and its requirement to show probable cause that a method or practice in pricing was unlawful.
Eli Lilly has said that the attorney general’s office engaged in a poor read of the act, an assertion that led the lower court to dismiss the case.
John O’Quinn, attorney for Eli Lilly, told the court that Smith and Liss were long-held precedent in consumer protection matters, and the Legislature has amended the act several times over. O’Quinn said that formed a “powerful chain” to show the high court, now, that the previous court’s decisions in those cases were correct.
“The Attorney General puts the cart before the horse in asking this court to decide the contours of an exemption, in the department’s words, an ‘affirmative defense’ as a threshold matter where the department has declined to show any legally viable violation has been alleged in the first place,” O’Quinn said. .
The case being mired in procedural intricacies led the justices to ask mostly technical questions about other cases that could or should be overturned and different ways those decisions might have been attacked by the attorney general, instead of insisting it could move forward under the consumer protection act.
But Chief Justice Megan Cavanagh pointedly asked Fowler if the manufacturer could have appealed the lower court’s finding of probable cause, which led to the issue of subpoenas.
Fowler said that under the act, Eli Lilly had to start with a motion to quash, but the company opted not to do that. The company, instead, brought a motion to stay the case in the circuit court, which was a different argument than what was before the court on Wednesday.
Overall, Fowler said the state believed that the initial petition jump started the controversy, showing there was a tangible legal dispute for the court to parse.
Nessel, Singh react to court hearing
Following the hearing, Nessel, in a statement, doubled down on her office’s assertion that the decisions preclude state investigations into suspected illegal business practices when that business sells products or services authorized for sale under state or federal law. The attorney general’s office said that was irrespective of whether there was an allegation on how that business conducted its affairs.
“Eli Lilly has relied on these past Supreme Court decisions that twist a narrow exemption into something far too broad,” Nessel said. “The Michigan Consumer Protection Act is supposed to protect consumers, but instead it often shields many corporations from any real accountability, even when their business practices are clearly egregious. People in Michigan expect this law to have their back, and it is my hope that the Court sides with the consumers who have been hurt by deceptive practices.”
State Sen. Sam Singh (D-East Lansing), the Senate’s majority floor leader, said in a statement that Michigan has had “worst-in-the-nation consumer protection laws” for too long, which have “left residents across the state vulnerable to exploitation and fraudulent business practices – in this case, drug manufacturers profiting off of people’s pain.”
“While it’s my hope that the outcome of this case sets the dial in the right direction, we must also change the laws on our books to prioritize protections for consumers over corporations,” Singh said. “By restoring power to the Michigan Consumer Protection Act and giving more tools to the Attorney General’s office to hold bad actors accountable, my legislation would give Michiganders the peace of mind they deserve as they go about their day-to-day activities and purchases.”
Singh introduced Senate Bill 134 to help bolster Michigan’s consumer protection statute, which was passed by the Senate in June.
The bill now sits in the House Judiciary Committee and has not yet had a hearing.
AG Nessel Beats Eli Lilly 4 To 3 At The Michigan Supreme Court
The Democrats on our Michigan Soviet Supreme Court overturned two precedent setting decisions — Smith v. Globe Life Insurance Co. (1999) and Liss v. Lewiston-Richards Inc. (2007) — that have long blocked attorneys general from investigating businesses already regulated by another agency. The MSC opinion in Nessel v. Eli Lilly & Co. (MSC 165961) hasn't yet been posted on the Michigan Supreme Court web site, but the deatils are circulating. The only real surprise was the close vote, 4 to 3.
This decision was closely watched by business groups across the country. It will confirm Michigan's hostile business environment and subjugation to MAJ to many business leaders. That sucking sound is getting louder:
Michigan Supreme Court overturns cases that blocked insulin pricing investigation
By Madalyn Buursma, Brad LaPlante - August 1, 2026LANSING, Mich. (WLNS) — The Michigan Supreme Court on Friday sided with Michigan’s attorney general, overturning two previous decisions that could have kept her from investigating insulin prices.
In a 4-3 decision, it ruled in favor of Michigan Attorney General Dana Nessel over Eli Lilly and overturning an exemption under the Michigan Consumer Protection Act.
The fight traces back to January 2022, when Nessel launched an investigation into Eli Lilly’s insulin pricing practices under the state’s consumer protection laws, alleging it had artificially increased the price of insulin medication. The drug maker pushed back, citing two Michigan Supreme Court decisions — Smith v. Globe Life Insurance Co. (1999) and Liss v. Lewiston-Richards Inc. (2007) — that have long blocked attorneys general from investigating businesses already regulated by another agency.
GOP bill aims to shield regulated businesses from lawsuits
Eli Lilly is regulated by the Food and Drug Administration and the Michigan Board of Pharmacy. Neither agency has authority over drug pricing.
An Ingham County Circuit Court judge sided with Eli Lilly in 2022, and the Michigan Court of Appeals upheld that ruling. Nessel appealed to the state Supreme Court, which heard oral arguments in November.
In Friday’s ruling, the court overturned both Smith v. Globe Life Insurance Co. and Liss v. Lewiston-Richards Inc.
Nessel in a statement celebrated the ruling, saying the state’s Consumer Protection Team “can go back to helping residents who have been deceived by licensed businesses.”
“Today is a great day for Michigan residents, and I am profoundly relieved that the Michigan Supreme Court finally restored the Consumer Protection Act to its true purpose,” she ruled. “What was once rendered toothless can now protect the people of our state who fall victim to predatory commercial operators.”
The Michigan Alliance for Legal Reform in a release said the decision exposes industries to “overlapping regulations, greater uncertainty, abusive litigation, and higher costs.”
“Today’s decision upends decades of settled case law, exposing workers and job providers alike to abusive litigation, duplicative red tape, and higher costs that will ultimately be passed along to Michigan consumers,” Zach Rudat, director of the Michigan Alliance for Legal Reform, said in a statement. “The Legislature must act now to codify the regulatory compliance exemption and restore clear, predictable standards for those already operating under extensive government oversight.”
The organization advocated for House Bill 5725. The bill, introduced by State Rep. Bill G. Schuette, R-Midland, would write a so-called “regulatory compliance exemption” directly into Michigan’s Consumer Protection Act.
Schuette previously said if the exemption is weakened, tradespeople and small businesses would be exposed to “tremendous amounts of litigation from money-hungry trial lawyers.”
Gov. Gretchen Whitmer in a social media post called Friday’s decision a “landmark victory for Michigan consumers.”
“This can protect consumers from predatory practices like needlessly raising the price of insulin,” she wrote. “For decades, Michiganders, unlike consumers in nearly every state, lacked an effective way to hold businesses accountable for unfair practices. I congratulate Attorney General Nessel on this win.”
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.





















